Pancreatic β cells are the only cells in the body that produce insulin, and are the cells whose malfunctioning is the proximate cause of diabetes. Consequently, repairing or replacing β cells is one of the major goals of diabetes research. In type I diabetes, where the immune system destroys β cells, need to be replaced outright. In type II diabetes, β cells “disappear” in another way. There is ample evidence that under conditions of chronic high blood sugar, such cells dedifferentiate, becoming less β cell-like over time. Read More
Synthetic cells (SCs) armed with recombinant growth factors could contribute to tissue regeneration and healing by promoting angiogenesis. This technology opens the door to its application in other therapies such as transplants that require the remodeling or formation of new blood vessels. In addition, they mark the way to produce intracorporeal biological drugs or the inhibition of the angiogenesis process itself when it comes to blocking the irrigation of a tumor. Read More
Iama Therapeutics Srl has sought new, selective inhibitors of solute carrier family 12 member 2 (NKCC1) to treat autism, Down syndrome and brain disorders featuring chloride (NKCC1/solute carrier family 12 member 5 [KCC2]) imbalance. Read More
Researchers from the University of Santiago de Compostela and University of Porto have reported the discovery of a novel acetylcholinesterase (AChE) inhibitor, MJM-255. Read More
Recent efforts have unveiled UCB-0022 (UCB Pharma Inc.) as an oral, brain-penetrant small molecule acting as a selective D1 positive allosteric modulator. Read More
Researchers from Sun Yat-sen University, Southern Medical University and Gannan Medical University reported the discovery of novel quinazoline-based KRAS G12C inhibitors as potential anticancer agents. Read More
Researchers from the U.K. have investigated the specificity and sensitivity of clonidine growth hormone (GH) as a biomarker for the differential diagnosis of multiple system atrophy (MSA) from pure autonomic failure (PAF), Parkinson’s disease (PD) and progressive supranuclear palsy (PSP). Read More
Aptabio Therapeutics Inc. has identified new pyrazole derivatives acting as reactive oxygen species (ROS) production inhibitors reported to be useful for the treatment of cancer, neurodegeneration, fibrosis, liver diseases and dermatological, eye and inflammatory disorders, among other disorders. Read More
Blossomhill Therapeutics Inc. has divulged macrocyclic compounds acting as epidermal growth factor receptor (EGFR: HER1; erbB1) and EGFR mutant inhibitors reported to be useful for the treatment of cancer. Read More
A series of novel tacrine derivatives acting as acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor subtype antagonists has been developed in research seeking to exploit these targets for the treatment of Alzheimer's disease. Read More
Research Triangle Institute (RTI International) has described new heteroaryl derivatives acting as apelin receptor (angiotensin-receptor like 1; APJ) agonists reported to be useful for the treatment of lung fibrosis. Read More
Oncolinx Pharmaceuticals LLC and the U.S. Department of Health and Human Services have presented new signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, and bacterial and viral infections. Read More
Invenra Inc. has announced preclinical data supporting the ongoing development of INV-322, a Sniper bispecific antibody co-targeting CTLA-4 and CD25 for cancer developed using Invenra's B-Body Platform. Read More
LG Chem Ltd. has synthesized new melanocortin 4 (MC4) receptor agonists reported to be useful for the treatment of obesity, diabetes, erectile dysfunction and inflammatory disorders. Read More
